Hollow Brook Wealth Management LLC Buys Shares of 5,532,951 Standard BioTools Inc. (NASDAQ:LAB)

Hollow Brook Wealth Management LLC bought a new stake in Standard BioTools Inc. (NASDAQ:LAB) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 5,532,951 shares of the company’s stock, valued at approximately $10,679,000. Standard BioTools accounts for about 3.2% of Hollow Brook Wealth Management LLC’s investment portfolio, making the stock its 6th largest position.

Several other institutional investors and hedge funds have also modified their holdings of LAB. MetLife Investment Management LLC grew its stake in shares of Standard BioTools by 86.3% during the 3rd quarter. MetLife Investment Management LLC now owns 143,325 shares of the company’s stock valued at $277,000 after buying an additional 66,410 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Standard BioTools by 188.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,445,083 shares of the company’s stock valued at $4,719,000 after acquiring an additional 1,597,728 shares in the last quarter. Intech Investment Management LLC purchased a new position in Standard BioTools in the third quarter valued at about $101,000. Royce & Associates LP boosted its stake in shares of Standard BioTools by 102.0% in the third quarter. Royce & Associates LP now owns 614,552 shares of the company’s stock valued at $1,186,000 after purchasing an additional 310,321 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in Standard BioTools by 433.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock valued at $35,000 after purchasing an additional 14,732 shares in the last quarter. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, TD Cowen decreased their price objective on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research report on Thursday, October 31st.

Standard BioTools Stock Up 1.1 %

Shares of NASDAQ:LAB opened at $1.84 on Monday. The firm has a 50-day simple moving average of $1.85 and a 200 day simple moving average of $2.00. Standard BioTools Inc. has a fifty-two week low of $1.21 and a fifty-two week high of $3.04. The company has a market cap of $684.96 million, a PE ratio of -2.59 and a beta of 1.57.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.